Open AccessPrognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer
Author(s) -
Pranav Murthy,
Mazen Zenati,
Amr I. Al Abbas,
Caroline Rieser,
Nathan Bahary,
Michael T. Lotze,
Herbert J. Zeh,
Amer H. Zureikat,
Brian A. Boone
Publication year - 2019
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-08094-0
Subject(s) - medicine , nat , surgical oncology , hazard ratio , gastroenterology , oncology , pancreatic cancer , neoadjuvant therapy , cancer , confidence interval , breast cancer , computer network , computer science
The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis. Neoadjuvant therapy (NAT) is increasingly used in the treatment of PDAC. However, biomarkers of response are lacking. This study aimed to determine the prognostic significance of SII before and after NAT and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9).